



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtivision.com

www.vtivisioninvestors.com (for investors)

ASX Announcement

RELEASE OF SECURITIES FROM ESCROW

Atlanta, Georgia, USA 19 March 2019: Visioneering Technologies, Inc (ASX: VTI or the 'Company'), advises of the expiry of the ASX imposed twenty-four (24) month escrow that was placed on certain securities.

This escrow was scheduled to expire on 27 March 2019, and in accordance with ASX Listing Rule 3.10A no less than ten (10) business days' notice is required. Accordingly, the restriction will be lifted on 2 April 2019.

The number and securities being released are as follows:

- 8,036,644 Shares (equivalent to the same number of CDIs)
- 150,576 CDIs (equivalent to the same number of Shares)
- 6,319,300 Options to be exercised into Shares (equivalent to the same number of CDIs)

Julian Rockett

Company Secretary

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. . VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHESS Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.